非洲超说明书使用氯喹和羟氯喹治疗COVID-19:违背WHO建议
本文综述非洲国家在WHO建议之外超说明书使用氯喹和羟氯喹治疗COVID-19的情况。数据检索自Scopus、PubMed、Hindawi、Google Scholar及本地和国际媒体。结果显示,许多非洲国家已在国家层面批准使用这些药物治疗COVID-19,与WHO警告相悖;部分非洲国家还出现了伪劣和不合标准氯喹产品。作者认为非洲政府卫生部门应批判性比较风险与获益,WHO和非洲药品监管机构应干预以停止超说明书使用和伪劣产品流通。
要点
- 许多非洲国家已在国家层面批准使用氯喹和羟氯喹治疗COVID-19,与WHO警告相悖。
- 部分非洲国家已出现伪劣和不合标准氯喹产品。
- WHO在《柳叶刀》研究发表后宣布这些药物的临床试验暂停。
- FDA曾发布紧急使用授权允许这些药物用于治疗COVID-19,而欧洲药品管理局警告不要广泛使用。
- 作者认为非洲政府卫生部门应批判性比较风险与获益,WHO和非洲药品监管机构应干预。
研究设计与关键结果
- 本文为综述,检索Scopus、PubMed、Hindawi、Google Scholar及本地和国际媒体,结果显示许多非洲国家已在国家层面批准使用氯喹和羟氯喹治疗COVID-19,与WHO警告相悖;部分非洲国家出现伪劣和不合标准氯喹产品。
对床旁实践的改变
- 作者认为,非洲政府卫生部门在使用这些药物前应批判性比较风险与获益;WHO和非洲药品监管机构应干预,以停止违背许可用途的超说明书使用及伪劣和不合标准产品在非洲大陆的流通。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「证据类型、等级与局限」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
COVID-19 is continuing as a big challenge for the globe and several types of research are continued to find safe and effective treatment and preventive options. Although there is a lack of conclusive evidence of their benefit, there is worldwide controversy to use anti-malarial drugs, hydroxychloroquine and chloroquine, for the treatment of COVID-19. FDA issued an emergency use authorization to the use of these drugs for the treatment of COVID-19. On the contrary to the FDA, the European Medicines Agency has warned against the widespread use of these drugs to treat COVID-19. Finally, the WHO declared that clinical trials on these drugs are halted after the devastating findings of the study published in the medical journal called The Lancet. Against this fact, there are several rumors about the irresponsible use of these drugs in Africa for the treatment of COVID-19. This work aimed to review the off-label use of these drugs for the treatment of COVID-19 in African countries against WHO recommendation. Data on the use of these drugs for the treatment of COVID-19 in African countries were searched from credible sources including Scopus, PubMed, Hindawi, Google Scholar, and from local and international media. The study showed that many African countries have already approved at the national level to use these drugs to treat COVID-19 by opposing WHO warnings. In addition to this, falsified and substandard chloroquine products started to emerge in some African countries. The health sectors of the African government should critically compare the risks and benefits before using these drugs. The WHO and African drug regulatory organizations should intervene to stop the off-label use practice of these drugs against the licensed purpose and distribution of falsified and substandard products in the continent.
参考来源
- Belayneh A. Off-Label Use of Chloroquine and Hydroxychloroquine for COVID-19 Treatment in Africa Against WHO Recommendation. Res Rep Trop Med. 2020. PMID: 32982538. doi:10.2147/RRTM.S269936
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。